

Taiwan provisionally approves Dexamethasone to treat COVID-19

14 August 2020 | News

Taiwan temporarily affirmed the utilization of dexamethasone, a modest and broadly utilized steroid, to treat the new coronavirus



Taiwan Centers for Disease Control Provisionally Approves Dexamethasone, the relatively economical and widely-used steroid for the treatment and cure of COVID 19.

Based on the [RECOVERY trial](#) results out of Oxford in the UK, the U.S. NIH sought to place dexamethasone on the clinical guidelines. The trial researchers showed dexamethasone as the first drug to save lives of COVID-19 patients. Taiwan's Centres for Disease Control Deputy Director-General Chuang Jen-hsiang stated that though the Taiwanese regulatory agency has chosen to temporarily permit dexamethasone as a COVID-19 treatment, it still needs to undergo certain procedures before being administered to patients.

Currently, in Taiwan Remdesivir is in high demand after the intravenously-administered medicine helped to shorten hospital recovery times in a clinical trial. Taiwan had originally ordered 2,000 doses to arrive by the end of July, but had only 78 in stock, enough to treat 54 seriously-ill patients. The steroid-based antiviral drug Dexamethasone is approved due to the shortfall of the antiviral drug remdesivir on the island after the United States bought nearly all global supplies. Dexamethasone, a low-cost and widely-used steroid.

Japan last month also approved the use of dexamethasone to treat COVID-19.